Xeris Biopharma Holdings, Inc. (FRA:2B30)

Germany · Delayed Price · Currency is EUR

5.84

-0.09 (-1.52%)

At close: Jan 7, 2026

Revenue by Product

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	2014 - 2018
Period Ending	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	2014 - 2018
Gvoke, Keveyis and Recorlev	153.36M	Log In	Log In	Log In	Log In	Upgrade
Gvoke, Keveyis and Recorlev Growth	40.36%	Log In	Log In	Log In	Log In	Upgrade
Royalty, Contract and Other	10.55M	Log In	Log In	Log In	Log In	Upgrade
Royalty, Contract and Other Growth	971.07%	Log In	Log In	Log In	Log In	Upgrade

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	2014 - 2018
Period Ending	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	2014 - 2018
United States	163.91M	Log In	Log In	Log In	Log In	Upgrade
United States Growth	48.68%	Log In	Log In	Log In	Log In	Upgrade